WAYNE, Pa., May 22, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at multiple investor conferences in June. He will provide an overview of the company's novel abuse-deterrent platform and the progress being made with the lead abuse-deterrent product candidates at the following conferences:
Jefferies 2014 Global Health Care Conference
June 5 at 1:00 p.m.
New York City
JMP Securities Healthcare Conference
June 24 at 11:00 a.m.
The Westin New York Grand Central in New York City
Janney's 2nd Annual Healthcare 1x1 Corporate Access Day*
June 26
60 State Street, Boston, MA
The Jefferies and JMP presentations will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts.
*Mr. Radie will present to investors in one-on-one meetings rather than in a presentation. There will be no webcast.
About Egalet
Egalet Corporation is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications. Egalet has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient (API). Using its proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation, while also providing tailored release of the active pharmaceutical ingredient. Its lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for patients who are suffering with chronic pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment options are not enough. There are currently no commercially available abuse-deterrent formulations of morphine, and if approved, Egalet believes that Egalet-001 would fill a significant unmet need in the marketplace. Its second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for patients who are suffering with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are not enough. The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles. Visit www.egalet.com for more information.